CJC-1295 (No DAC) Half-Life: How Long It Stays Active

The short version

In animal models and preclinical assays, CJC-1295 (No DAC)—also designated as Modified GRF 1-29—demonstrates a biological half-life of approximately 30 minutes.

Unlike its acylated counterpart featuring the Drug Affinity Complex (DAC), this tetrasubstituted 29-amino acid peptide undergoes rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV) and fast renal elimination.

It acts as a growth hormone-releasing hormone (GHRH) receptor agonist, triggering a physiological pulse of growth hormone (GH) without sustaining elevated baseline hormone levels over extended periods.

This brief window of bioavailability makes it an essential tool for investigators studying natural pulsatile GH dynamics, receptor desensitization thresholds, and downstream insulin-like growth factor 1 (IGF-1) transcription in vitro and in vivo.

What Is CJC-1295 (No DAC) and How Does It Work in Research Models?

CJC-1295 (No DAC) is a synthetic analog of human growth hormone-releasing hormone (GHRH), specifically optimized from the native 44-amino acid sequence. Native GHRH undergoes extremely rapid clearance in biological systems, boasting an in vivo half-life of under 7 minutes. To improve metabolic stability while maintaining physiological receptor signaling, researchers modified the active N-terminal 1-29 amino acid sequence with four key amino acid substitutions at positions 2, 8, 15, and 27 (Ala2 -> D-Ala2, Gln8 -> Asp8, Gly15 -> Ala15, Leu27 -> Lys27).

These structural modifications protect the molecule against immediate cleavage by endopeptidases while preserving affinity for the GHRH receptor on anterior pituitary cells. When cjc 1295 binds to its target, it activates the adenylate cyclase pathway, increasing intracellular cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) signaling. This cascade stimulates the transcription and exocytosis of growth hormone.

Because of its physiological selectivity, CJC-1295 (No DAC) is primarily studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research. Researchers utilizing this peptide in laboratory models investigate cellular regeneration, nitrogen retention, collagen synthesis, and lipid oxidation pathways without forcing continuous, unphysiological pituitary overstimulation.

What Drives the CJC-1295 (No DAC) Half-Life in Preclinical Literature?

The primary factor determining the roughly 30-minute half-life of cjc no dac is its physiological interaction with endogenous proteolytic enzymes and clearance pathways. Although the substitutions at positions 2, 8, 15, and 27 significantly resist cleavage compared to native GHRH(1-29) amide, the unacylated peptide remains subject to enzymatic degradation by dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidases over time.

A secondary determinant is molecular weight and plasma protein binding. Weighing approximately 3,367 Daltons, the unbound peptide rapidly filters through the renal glomeruli. Unlike larger proteins or lipophilic compounds, CJC-1295 (No DAC) does not spontaneously bind to circulating serum albumin, leaving its hydrophilic structure fully exposed to renal filtration and metabolic breakdown.

Species differences also play a marked role in reported pharmacokinetics. Mouse and rat models exhibit higher metabolic rates and elevated plasma peptidase activity, often showing terminal elimination half-lives closer to 15 to 25 minutes. In canine and non-human primate studies, plasma retention extends slightly, yielding biological half-lives between 30 and 45 minutes. Researchers conducting quantitative assays must account for these species-specific clearance vectors when planning sampling schedules.

CJC-1295 (No DAC) vs. CJC-1295 (With DAC): Understanding the Structural Difference

The inclusion or omission of the Drug Affinity Complex (DAC) alters the pharmacokinetic profile of CJC-1295 dramatically. CJC-1295 with DAC incorporates a maleimido-propionic acid group attached via a lysine linker at the C-terminus. In biological fluid, this reactive linker forms a covalent bond with endogenous serum albumin at the Cys34 residue.

Albumin binding shields the peptide from enzymatic degradation and prevents renal filtration, extending the elimination half-life from ~30 minutes to up to 6–8 days in preclinical models. This creates a persistent elevated baseline of GH and downstream IGF-1 release.

In contrast, CJC-1295 (No DAC) lacks this reactive linker. It cleared rapidly, allowing pituitary cells to recover and re-sensitize between exposure windows. For researchers studying pulsatile, physiological GH surges without altering baseline hormone concentration or risking receptor downregulation, the short-acting CJC-1295 (No DAC) is the standard experimental molecule. Browse our complete catalog of research peptides to view both GHRH analogs.

How CJC-1295 (No DAC) Compares to Other Secretagogues

To evaluate experimental design parameters, researchers frequently compare the half-life and mechanism of CJC-1295 (No DAC) against other GHRH analogs and growth hormone secretagogues (GHRPs). The following breakdown details how these molecules behave in biological systems:

1. Mod GRF 1-29: Identical in chemical sequence to CJC-1295 (No DAC). The terms are used interchangeably in biochemical literature. Exhibits a 30-minute half-life and selective GHRH receptor activity.

2. CJC-1295 With DAC: Acylated GHRH analog with a covalent albumin-binding affinity. Half-life ranges from 6 to 8 days, producing sustained elevated GH levels rather than pulsatile pulses.

3. Ipamorelin: A selective ghrelin/GHRP receptor agonist with a half-life of ~2 hours in preclinical rodent models. Often evaluated alongside GHRH analogs in dual-receptor activation studies.

4. GHRP-2: A potent ghrelin receptor agonist with a half-life of 45 to 60 minutes. Triggers rapid GH release alongside minor transient elevations in cortisol and prolactin in vitro.

When evaluating combination dynamics, such as dual-stimulation models involving cjc ipamorelin, researchers leverage the complementary mechanisms of action: GHRH receptor activation paired with ghrelin receptor activation to observe synergistic GH release curves.

Impact of Half-Life on In Vitro and In Vivo Assay Timing

Because CJC-1295 (No DAC) exhibits rapid clearance, timing is critical when measuring primary endpoint markers in biological assays. In cell culture models (e.g., primary anterior pituitary cell cultures), maximum cAMP generation occurs within 10 to 15 minutes of receptor exposure, followed by a peak in GH concentration in media supernatants at the 30- to 45-minute mark.

In animal models, plasma growth hormone spikes sharply between 15 and 30 minutes following administration, returning to baseline within 90 to 120 minutes. Downstream transcriptional markers, such as hepatic IGF-1 messenger RNA expression, peak approximately 2 to 4 hours post-exposure, with serum IGF-1 protein concentrations rising gradually over 6 to 12 hours.

Researchers conducting pharmacokinetic or pharmacodynamic experiments must structure blood sampling or media collection windows closely around these physiological inflection points. Missing the narrow 30-minute peak window can lead to inaccurate baseline measurements or underestimated peptide potency.

Standardizing Peptide Quality: How Half-Life Studies Require Verified Purity

Pharmacokinetic data, including half-life calculations, can be severely skewed by peptide impurities, sequence truncations, or residual trifluoroacetic acid (TFA). Impurities such as truncated deletion sequences (e.g., des-Ala1 or des-Lys27 fragments) compete for GHRH receptor sites without inducing full agonist activity, distorting receptor binding kinetics.

Furthermore, unremoved TFA salts or high heavy-metal contaminants destabilize peptide reconstitutions in aqueous buffers, causing accelerated non-enzymatic hydrolytic degradation prior to assay introduction. This artificial breakdown yields prematurely shortened half-life figures that do not accurately reflect true peptide clearance.

To ensure precise, reproducible pharmacokinetic outcomes, research laboratories require peptides verified by High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS). Learning more about peptide purity testing standards helps research teams establish strict quality controls for incoming analytical samples.

Evaluating Peptide Suppliers for Pharmacokinetic Research

When selecting a vendor for GHRH analogs, commercial research facilities must evaluate suppliers across strict analytical and operational criteria. Below is a structured benchmark comparison for evaluating peptide quality:

Purity Verification: Insist on lot-specific HPLC chromatograms demonstrating >= 99% peptide purity. Vendors providing generic, non-lot-matched analytical reports present compliance risks.

Mass Traceability: Confirm molecular mass via High-Resolution Mass Spectrometry (HRMS) or MALDI-TOF to guarantee exact amino acid sequence fidelity and complete absence of deletion peptides.

Endotoxin Quantification: Verify that bacterial endotoxin levels are measured using Limulus Amebocyte Lysate (LAL) testing, with certified values falling below < 0.01 EU/mg for biological safety.

Domestic USA Synthesis: Prefer vendors manufacturing and processing peptides within accredited US facilities to avoid international shipping delays, temperature fluctuations, and customs degradation.

Cold-Chain Handling & Fast Transit: Verify same-day dispatch capabilities with controlled climate packaging to preserve tertiary peptide structure during transit.

Transparent Documentation: Ensure complete batch traceability with immediate public or QR-code access to full analytical testing suites.

Red Flags When Sourcing GHRH Peptides for Laboratory Research

To safeguard research budgets and project integrity, buyers should recognize red flags common among non-compliant or low-tier peptide distributors:

1. Missing Batch-Specific COAs: Avoid suppliers that display a single static COA on their product page rather than providing independent third-party analytical reports tied directly to the lot number on your vial.

2. Medical or Human Dosing Claims: Any vendor offering protocols, human dosing calculators, reconstitution instructions for personal use, or therapeutic claims is operating outside research compliance and risk providing non-certified, sub-analytical grade material.

3. Lack of Endotoxin Testing: Raw peptide powder can meet 98% purity targets while carrying toxic endotoxin levels from bacterial expression or improper processing, leading to cellular toxicity in cell culture models.

4. Unusually Cheap Pricing Without Proof: Extremely low prices frequently indicate overseas sourcing of unrefined crude peptides with high TFA content and unknown degradation profiles.

5. Opaque Shipping Practices: Vials shipped without thermal buffers or from non-verifiable residential fulfillment nodes compromise peptide integrity through environmental stress.

Ordering CJC-1295 (No DAC) from PX1 Research

PX1 Research is a dedicated USA-based supplier of high-purity analytical compounds engineered for rigor and reproducibility. When you buy from PX1 Research, you receive high-grade material manufactured under strict quality standards to ensure predictable experimental results in every assay.

When you order CJC-1295 No DAC 2 mg, 5 mg, or 10 mg vials, your order ships directly from our climate-controlled dispatch facilities in California and Arizona. Orders placed before 3:00 PM EST Monday through Friday ship the same day via tracked domestic transit, packaged to protect lyophilized peptide matrix integrity.

Every single lot of CJC-1295 (No DAC) is backed by an independent third-party Certificate of Analysis verifying purity >= 99% via HPLC, exact molecular weight confirmation via Mass Spectrometry, and low endotoxin levels. Access your batch COA instantly online or reach out to our dedicated support team for technical documentation. Visit our catalog today to purchase CJC-1295 (No DAC) for laboratory research or contact our team for bulk peptide wholesale inquiries.